-
Detailed Analysis Download Full Stock Report Add to Watchlist
Values as of: 2022-05-21
Last Closing Price
USD 7.89Change
0.00 (0.00)%Market Cap
USD 0.77BYahoo Analyst Target
USD 8.00 (1.39%)Avg Analyst Target
N/A
N/A
Verdict
Values as of: 2022-05-21
Last Closing Price
USD 7.89Change
0.00 (0.00)%Market Cap
USD 0.77BYahoo Analyst Target
USD 8.00 (1.39%)Avg Analyst Target
N/AN/A
Verdict
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesth ...Read More
Employees : 87
Fiscal Year End : June
Currency: USD
Country : USA
Beta : 1.77
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
SSNLF | Samsung Electronics Co. Ltd |
N/A |
USD15,011.80B | 9.00 | N/A |
DISPF | Disco Corporation |
N/A |
USD3,369.71B | 18.60 | -488.90 |
BMYMP | Bristol-Myers Squibb Company P.. |
N/A |
USD2,077.79B | 5,631.11 | N/A |
CHKDJ | Chesapeake Energy Corporation .. |
N/A |
USD1,315.84B | N/A | N/A |
BAMKL | Bank of America Corporation |
N/A |
USD267.26B | 9.28 | N/A |
UNLNF | Unilever N.V |
N/A |
USD158.01B | 24.49 | N/A |
LLOBF | Lloyds Banking Group plc 9.25%.. |
N/A |
USD134.80B | N/A | N/A |
NONEY | Net One Systems Co. Ltd |
N/A |
USD109.44B | 1,364.40 | N/A |
AZSEY | Allianz SE |
N/A |
USD103.32B | 11.82 | N/A |
SHPGF | Shire plc |
N/A |
USD57.84B | 24.90 | N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|
N/A
Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | 471.74% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 471.74% | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 120.74% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 120.74% | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 191.72% | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | 62.98% | N/A | N/A | N/A | N/A | ||
Market Capitalization | 0.77B | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 87%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
Market Value | |||||||
Price / Earning Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price/Book Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price / Cash Flow Ratio | -39.72 | N/A | N/A | N/A | N/A | ||
EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
Management Effectiveness | |||||||
Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
Return on Invested Capital | -143.31% | N/A | N/A | N/A | N/A | ||
Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
Debt to Equity Ratio | N/A | N/A | N/A | N/A | N/A | ||
Technical Ratios | |||||||
Dividend Yield | N/A | N/A | N/A | N/A | N/A | ||
Short Ratio | N/A | N/A | N/A | N/A | N/A | ||
Short Percent | N/A | N/A | N/A | N/A | N/A | ||
Beta | 1.77 | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
No discussions yet
User Name | Target Rating | Target Horizon (Months) | Target Price | User Analysis | Date | Comment |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
The company had negative total cash flow in the most recent four quarters.